• Home
  • About
  • Approach
  • Pipeline
  • News & Resources
  • Contact
Menu
  • Home
  • About
  • Approach
  • Pipeline
  • News & Resources
  • Contact

Creating targeted immunotherapies for treatment-resistant cancers.

Creating targeted immunotherapies for treatment-resistant cancers.

About Duet

Duet BioTherapeutics is a clinical-stage immuno-oncology company creating a new category of bifunctional and cell-selective oligonucleotide treatments designed to target dormant immune cells within the tumor microenvironment. Targeted activation of these antigen-presenting cells removes the immunosuppressive shield around the tumor and jump-starts T cell-mediated immune responses to kill cancer cells.

LEARN MORE ABOUT DUET

Our Approach

The unique mechanism-of-action of these synthetic oligos comes from simultaneously targeting two intracellular immune pathways, signal transducer and activator of transcription 3 (STAT3) and toll-like receptor 9 (TLR9). The targeted inhibition of STAT3, a master immune checkpoint inhibitor, reawakens immune cells and allows for the full potential of TLR9-driven immune responses.

LEARN MORE ABOUT
OUR SCIENTIFIC APPROACH

Our Pipeline

The broad, anticancer efficacy of these bifunctional and cell-selective oligos has been verified in numerous animal studies, using both human and mouse tumor models. These preclinical results underscore the therapeutic potential not only for blood cancers but also for the most aggressive solid tumors, such as metastatic prostate cancers.

LEARN MORE ABOUT
Duet's Pipeline

Recent News & Resources

Press Releases

Scopus BioPharma’s Subsidiary — Duet BioTherapeutics — to Present at the 3rd Annual STING & TLR-Targeting Therapies Summit

Read more

Video & Presentations

https://duettx.com/wp-content/uploads/Scopus-BioPharma-Presentation-on-Launch-of-Duet-Therapeutics-at-H.C.-Wainwright-23rd-Annual-Global-Investment-Conference.mp4
Featured Video Play Icon

Scopus Presentation on Launch of Duet Therapeutics, its Wholly-Owned Subsidiary Focused on Immuno-Oncology

Read more

Press Releases

Scopus BioPharma to Present at the LD Micro Main Event

Read more
  • Home
  • About
  • Approach
  • Pipeline
  • News & Resources
  • Contact
Menu
  • Home
  • About
  • Approach
  • Pipeline
  • News & Resources
  • Contact

© 2022 Duet BioTherapeutics. All rights reserved | Privacy Policy | Cookies Policy